Immunology Graduate Group

Terri M. Laufer, M.D.
Assistant Professor, Division of Rheumatology
Department of Medicine

Address: Biomedical Research Building II/III, Room 753
Office Phone: (215) 573-2955
Fax: (215) 573-7599
Email: tlaufer@mail.med.upenn.edu

Education:
A.B., Biochemistry, Princeton University
M.D., Columbia College of Physicians and Surgeons
Post-doctoral fellow, Harvard University

Research Interests

Thymic development and peripheral activation of autoreactive T cells; Requirements for tissue-specific expression of MHC class II molecules.

Research Techniques:

A transgenic approach is utilized to examine the immunologic sequelae of limiting MHC class II expression to subpopulations of professional antigen presenting cells, i.e. thymic epithelium, B cells, or dendritic cells. Cellular and molecular techniques including adoptive transfers, proliferation assays, and flow cytometric analysis are performed to understand the development of CD4+ T cells and the specificity and function of those T cells.

Research Summary
 
Major histocomatibility complex (MHC) class II molecules are required for the normal development in the thymus of CD4+ T cells and function to present peptide antigens to those CD4 cells in the periphery.

The distribution of class II molecules is limited to thymic epithelial cells-where they are required for the positive and negative selection of CD4+ T cells-and in the periphery where they are required for the survival and activation of those T cells. We have developed a series of transgenic mice with restricted expression of the MHC class II molecule, I-Ab, and used them to investigate the requirement for different populations of antigen presenting cells in the thymic selection, peripheral activation, and tolerance of CD4+ T cells. Our most well studied model is the K14 mouse in which MHC molecules are restricted to thymic cortical epithelium-both thymic medullary epithelium and bone marrow-derived cells are class II negative. Positive selection of CD4+ T cells does occur in the K14 thymus; however, clonal deletion of autoreactive thymocytes can not be detected. Thus, K14 CD4 cells proliferate to I-Ab-positive APC in vitro and cause graft-versus-host disease when injected into MHC-identical hosts. Our current studies are directed toward understanding the peptide specificity, function, and pathologic potential of these autoreactive T cells:

1) Examination of a series of K14-derived autoreactive T hybridomas demonstrates that the autoreactive population of CD4 cells is polyclonal; however, we are beginning to identify the individual peptides responsible for stimulating the autoreactive response. To better understand the thymic selection processes in both K14 and wildtype thymi, we have also derived TCR transgenics from two of the hybrids and have begun to analyze the thymic development and peripheral function of autoreactive TCR transgenic CD4+ T cells in both K14 and wildtype mice of various haplotypes, including NOD, the diabetogenic genotype.

2) Development of autoimmunity: Adoptive transfer systems are being utilized to tease apart the T cell and target-organ abnormalities that must be present to initiate an autoimmune disease. Disease models include graft-versus-host disease, Herpes simplex keratitis, and Type I diabetes.

3) Requirement for MHC class II in other antigen presenting populations. Our newest transgenics utilize the mb-1 and CD11c promoters to reexpress class II molecules in the B cells and dendritic cells, respectively, of class II-deficient mice. Studies will be directed towards understanding how limiting the expression of Class II molecules alters the positive and negative selection, peripheral survival, and peripheral survival and effector function of CD4+ T cells.

Key Words:

T cell development, autoimmunity, transgenesis, MHC class II function.

 

Biomedical Graduate Studies | University of Pennsylvania | Contact